» Articles » PMID: 10561319

Survival and Prognostic Stratification of 670 Patients with Advanced Renal Cell Carcinoma

Overview
Journal J Clin Oncol
Specialty Oncology
Date 1999 Nov 24
PMID 10561319
Citations 563
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To identify prognostic factors and a model predictive for survival in patients with metastatic renal-cell carcinoma (RCC).

Patients And Methods: The relationship between pretreatment clinical features and survival was studied in 670 patients with advanced RCC treated in 24 Memorial Sloan-Kettering Cancer Center clinical trials between 1975 and 1996. Clinical features were first examined univariately. A stepwise modeling approach based on Cox proportional hazards regression was then used to form a multivariate model. The predictive performance of the model was internally validated through a two-step nonparametric bootstrapping process.

Results: The median survival time was 10 months (95% confidence interval [CI], 9 to 11 months). Fifty-seven of 670 patients remain alive, and the median follow-up time for survivors was 33 months. Pretreatment features associated with a shorter survival in the multivariate analysis were low Karnofsky performance status (<80%), high serum lactate dehydrogenase (> 1.5 times upper limit of normal), low hemoglobin (< lower limit of normal), high "corrected" serum calcium (> 10 mg/dL), and absence of prior nephrectomy. These were used as risk factors to categorize patients into three different groups. The median time to death in the 25% of patients with zero risk factors (favorable-risk) was 20 months. Fifty-three percent of the patients had one or two risk factors (intermediate-risk), and the median survival time in this group was 10 months. Patients with three or more risk factors (poor-risk), who comprised 22% of the patients, had a median survival time of 4 months.

Conclusions: Five prognostic factors for predicting survival were identified and used to categorize patients with metastatic RCC into three risk groups, for which the median survival times were separated by 6 months or more. These risk categories can be used in clinical trial design and interpretation and in patient management. The low long-term survival rate emphasizes the priority of clinical investigation to identify more effective therapy.

Citing Articles

Prognostic Value of Hemoglobin, Albumin, Lymphocyte, Platelet (HALP) Score in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab.

Tomcova Z, Obertova J, Chovanec M, Sycova-Mila Z, Stefanikova K, Slachtova E Biomedicines. 2025; 13(2).

PMID: 40002897 PMC: 11852442. DOI: 10.3390/biomedicines13020484.


Prognostic significance of peripheral blood biomarkers in patients with advanced renal cell carcinoma treated with nivolumab and ipilimumab-a polish multicenter, observational study.

Pacholczak-Madej R, Drobniak A, Grela-Wojewoda A, Calik J, Viegas N, Tusien-Malecka D Clin Exp Med. 2025; 25(1):45.

PMID: 39849293 PMC: 11759459. DOI: 10.1007/s10238-024-01544-4.


Longitudinal Testing of Circulating Tumor DNA in Patients With Metastatic Renal Cell Carcinoma.

Basu A, Au C, Kommalapati A, Kandala H, Sudhaman S, Mahmood T JCO Precis Oncol. 2024; 8:e2400667.

PMID: 39693589 PMC: 11670910. DOI: 10.1200/PO-24-00667.


Identifying an Inversin as a Novel Prognostic Marker in Patients with Clear-Cell Renal Cell Carcinoma.

Urlic I, Soljic V, Vukoja M, Marijanovic I, Kraljevic M, Urlic M Int J Mol Sci. 2024; 25(22).

PMID: 39596188 PMC: 11594840. DOI: 10.3390/ijms252212120.


PrimerX: A Bayesian Multistage Cohort Embedded Randomised Trial to Evaluate the Role of Deferred Local Therapy of the Primary Tumour in Combination with Immune Checkpoint Inhibitor-based First-line Therapy in Metastatic Renal Cell Carcinoma Patients.

Figaroa O, Zondervan P, Kessels R, Berkhof J, Aarts M, Hamberg P Eur Urol Open Sci. 2024; 70:28-35.

PMID: 39483517 PMC: 11525453. DOI: 10.1016/j.euros.2024.09.002.